Evidence map›Paper›PMID 40535840›Full record

ArticleRSC medicinal chemistry2025

Novel furo[2,3-

M A M Abdel Reheim, Walid E Elgammal, Mahmoud S Bashandy, Mohammed I A Hamed, Asmaa M AboulMagd, Mona G Khalil, Amr M Abdou, Rasha A Hassan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M A M Abdel ReheimDepartment of Chemistry, Faculty of Science, Arish University Arish 45511 Egypt.
Walid E ElgammalChemistry Department, Faculty of Science, Al-Azhar University Nasr City Cairo Egypt.ORCID https://orcid.org/0000-0002-5982-5635
Mahmoud S BashandyChemistry Department, Faculty of Science, Al-Azhar University Nasr City Cairo Egypt.
Mohammed I A HamedDepartment of Organic and Medicinal Chemistry, Faculty of Pharmacy, Fayoum University Fayoum 63514 Egypt.
Asmaa M AboulMagdDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University Beni Suef Egypt.ORCID https://orcid.org/0000-0003-4243-9401
Mona G KhalilPharmacology and Toxicology Department, Faculty of Pharmacy, Modern University for technology and Information Cairo Egypt.
Amr M AbdouDepartment of Microbiology and Immunology, National Research Centre Dokki Giza 12622 Egypt amrkheir@yahoo.com.ORCID https://orcid.org/0000-0002-3373-2406
Rasha A HassanPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University Cairo Egypt.ORCID https://orcid.org/0000-0002-6785-6394

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to synthesize a series of innovative improved anticancer chemical entities by combining the unique advantages of 1,3,4-thiadiazole as an established anticancer pharmacophore with the furopyrimidine scaffold which is a key component of many reported cytotoxic agents. Sixteen furopyrimidine derivatives were designed and evaluated by several biological tests including antiproliferative activity against 60 human cancer cell lines, measurement of GI

Identifiers

PMID40535840
PMCPMC12171737

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.